Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


USV inaugurates injectables facility in India

This article was originally published in Scrip

Executive Summary

USV of India has inaugurated its first sterile injectables facility in Daman, about 150kms from Mumbai. Set up with an investment of Rs500 million ($10.7 million), the new facility is equipped to handle a range of products involving recombinant proteins, peptides, small-molecule formulations and ophthalmic preparations. It has the capacity to produce 8.6 million vials on an annualised basis. The plant is also equipped with an ophthalmic formulation filling line and can produce more than five million vials. The new facility is expected to cater to the requirements of the US and European markets and USV expects to file for a FDA audit soon. USV, which is the leading manufacturer of metformin globally, is also developing a pipeline of biotechnology products and vaccines in India. It is developing vaccines for typhoid and hepatitis C and looking at in-licensing opportunities for vaccines for dengue and chikungunya, the company told Scrip earlier this year.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts